BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26836429)

  • 21. Biosimilar insulins: guidance for data interpretation by clinicians and users.
    Heinemann L; Home PD; Hompesch M
    Diabetes Obes Metab; 2015 Oct; 17(10):911-8. PubMed ID: 25974131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The biosimilar insulin landscape: current developments.
    Lavalle-González FJ; Khatami H
    Postgrad Med; 2014 Oct; 126(6):81-92. PubMed ID: 25414937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
    Moodie P
    N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582
    [No Abstract]   [Full Text] [Related]  

  • 24. The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.
    Saunders H; Pham B; Loong D; Mishra S; Ashoor HM; Antony J; Darvesh N; Bains SK; Jamieson M; Plett D; Trivedi S; Yu CH; Straus SE; Tricco AC; Isaranuwatchai W
    Value Health; 2022 Jul; 25(7):1235-1252. PubMed ID: 35341688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in insulin therapy: a review of insulin degludec.
    King A
    J Fam Pract; 2012 May; 61(5 Suppl):S28-31. PubMed ID: 22577639
    [No Abstract]   [Full Text] [Related]  

  • 27. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Practical aspects in the use of biosimilar insulins].
    Krämer I; Blüher M; Kuhlmann MK; Heinemann L
    Dtsch Med Wochenschr; 2016 Oct; 141(21):1565-1568. PubMed ID: 27750344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lantus or lente insulin? The confusion builds.
    Cohen MR
    Nursing; 2003 Sep; 33(9):12. PubMed ID: 14562818
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of diabetic cats with long-acting insulin.
    Roomp K; Rand JS
    Vet Clin North Am Small Anim Pract; 2013 Mar; 43(2):251-66. PubMed ID: 23522171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biosimilars for insulin: a cost-saving alternative?
    McCall C
    Lancet; 2018 Aug; 392(10146):463-464. PubMed ID: 30129449
    [No Abstract]   [Full Text] [Related]  

  • 32. Biosimilar insulins are coming: the top 10 things you should know.
    Blumer I; Edelman S
    Postgrad Med; 2014 May; 126(3):107-10. PubMed ID: 24918796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Newer basal insulin analogues: degludec, detemir, glargine.
    Kalra S
    J Pak Med Assoc; 2013 Nov; 63(11):1442-4. PubMed ID: 24392539
    [No Abstract]   [Full Text] [Related]  

  • 34. Biosimilar insulins.
    Heinemann L
    Expert Opin Biol Ther; 2012 Aug; 12(8):1009-16. PubMed ID: 22583127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm].
    Haluzík M
    Vnitr Lek; 2017; 63(2):87-92. PubMed ID: 28334539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Newer Long-Acting Insulins on Hypoglycemia and Fracture Risk Among People with Diabetes: A Systematic Review.
    Hangaard S; Jensen MH
    Curr Osteoporos Rep; 2021 Dec; 19(6):637-643. PubMed ID: 34741730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice.
    J Am Assoc Nurse Pract; 2018 Jul; 30(7):381-382. PubMed ID: 29979296
    [No Abstract]   [Full Text] [Related]  

  • 38. [New insulins in diabetes therapy].
    Morell B
    Schweiz Med Wochenschr; 1979 Mar; 109(10):362-5. PubMed ID: 570723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Administration of Biosimilar Insulin Analogs: Role of Devices.
    Heinemann L; Fritz I; Khatami H; Edelman SV
    Diabetes Technol Ther; 2017 Feb; 19(2):79-84. PubMed ID: 28118050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin biosimilars: the impact on rapid-acting analogue-based therapy.
    Franzè S; Cilurzo F; Minghetti P
    BioDrugs; 2015 Apr; 29(2):113-21. PubMed ID: 25773234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.